Lilly’s retatrutide trial shows Type 2 diabetes patients lost up to 60 pounds over 80 weeks
AI Market Summary
Late-stage trial results for Eli Lilly's retatrutide published in The Lancet and NEJM show unprecedented weight loss in Type 2 diabetes and obesity populations, alongside meaningful A1C reductions and potential remission signals. The data strengthen Lilly's GLP-1 franchise narrative ahead of an expected FDA filing and can raise expectations for future market share and pricing power, while highlighting regulatory and competitive risks from unauthorized copycats.
Impact level
● Medium
Affected assets
NCSKLLY2USD/USDT+0.07%
AI Insight · NCSKLLY2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Eli Lilly’s GLP-1 drug retatrutide posted late-stage results in The Lancet and the New England Journal of Medicine. The data showed people with Type 2 diabetes lost up to 60 pounds (about 23%), while obese patients without diabetes lost up to 70 pounds (about 25%). The trials also found up to 40% of patients reached an A1C below 5.7%, under the threshold used to diagnose diabetes and prediabetes.
